20 September 2022 - Novartis Pharmaceuticals Canada and the pan Canadian Pharmaceutical Alliance have successfully concluded negotiations for Luxturna (voretigene neparvovec), a one-time gene therapy for the treatment of adult and paediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations.

"We are thrilled to have positively completed these negotiations for Luxturna, one of two pioneering targeted gene therapies Novartis has introduced in Canada for patients and families devastated by rare, debilitating or life-threatening genetic diseases. For all Canadians who urgently need treatment with this innovative therapy, this is an important step to achieve access," said Andrea Marazzi, Country President, Novartis Canada. "We will continue to work collaboratively with provincial and territorial jurisdictions so that patients whose vision is impaired as a result of a mutation in both copies of the RPE65 gene can have access to Luxturna through public drug plans as quickly as possible."

Read Novartis press release